LON:GNS Genus (GNS) Share Price, News & Analysis GBX 1,514 -2.00 (-0.13%) (As of 12/20/2024 12:01 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider Trades About Genus Stock (LON:GNS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genus alerts:Sign Up Key Stats Today's Range 1,485.26▼ 1,53650-Day Range 1,514▼ 2,11052-Week Range 1,478▼ 2,378Volume246,472 shsAverage Volume124,705 shsMarket Capitalization£992.73 millionP/E Ratio12,616.67Dividend Yield2.11%Price TargetGBX 2,150Consensus RatingBuy Company OverviewGenus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.Read More… Genus Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks29th Percentile Overall ScoreGNS MarketRank™: Genus scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenus has only been the subject of 1 research reports in the past 90 days.Read more about Genus' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genus is 12,616.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 113.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Genus is 12,616.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 90.13.Price to Earnings Growth RatioGenus has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenus has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GNS. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldGenus pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGenus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Genus is 26,666.67%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Genus' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for GNS. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 4 people have searched for GNS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Genus to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.75% of the stock of Genus is held by insiders.Percentage Held by Institutions77.79% of the stock of Genus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Genus' insider trading history. Receive GNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter. Email Address GNS Stock News HeadlinesGenus' (GNS) Buy Rating Reiterated at Shore CapitalDecember 14, 2024 | americanbankingnews.comWith 82% ownership, Genus plc (LON:GNS) boasts of strong institutional backingNovember 28, 2024 | finance.yahoo.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…December 22, 2024 | Investors Alley (Ad)British Blues sell to 6000gns at CCM Skipton autumn highlightNovember 8, 2024 | uk.news.yahoo.comThere May Be Some Bright Spots In Genus' (LON:GNS) EarningsOctober 22, 2024 | finance.yahoo.comGenus (LON:GNS) Has Affirmed Its Dividend Of £0.217October 17, 2024 | finance.yahoo.comGenus plc (GNS.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comGenus And 2 Other Undervalued Small Caps With Insider Buying To Enhance Your PortfolioSeptember 18, 2024 | finance.yahoo.comSee More Headlines GNS Stock Analysis - Frequently Asked Questions How have GNS shares performed this year? Genus' stock was trading at GBX 2,170 at the start of the year. Since then, GNS stock has decreased by 30.2% and is now trading at GBX 1,514. View the best growth stocks for 2024 here. How do I buy shares of Genus? Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Genus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genus investors own include Meta Platforms (META), Lloyds Banking Group (LLOY), Rolls-Royce Holdings plc (RR.L), AstraZeneca (AZN), Barclays (BARC), BP (BP) and Clinigen Group (CLIN). Company Calendar Ex-Dividend for 12/6 Dividend11/07/2024Dividend Payable12/06/2024Today12/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPersonal Services Current SymbolLON:GNS CUSIPN/A CIKN/A Webwww.genusplc.com Phone+44-1256-347100FaxN/AEmployees480Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,150 High Stock Price TargetGBX 2,150 Low Stock Price TargetGBX 2,150 Potential Upside/Downside+42.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.12 Trailing P/E Ratio12,616.67 Forward P/E Ratio21.33 P/E Growth2.87Net Income£7.90 million Net Margins1.18% Pretax MarginN/A Return on Equity0.43% Return on Assets3.31% Debt Debt-to-Equity Ratio53.54 Current Ratio1.80 Quick Ratio1.08 Sales & Book Value Annual Sales£668.80 million Price / Sales1.48 Cash FlowGBX 29.94 per share Price / Cash Flow50.56 Book ValueGBX 835 per share Price / Book1.81Miscellaneous Outstanding Shares65,570,000Free FloatN/AMarket Cap£992.73 million OptionableNot Optionable Beta0.37 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (LON:GNS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genus plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Genus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.